.jpg)
.png)
As an Internist who specialized in adult medicine, I had not seen many pediatric patients since my days in medical school. Now, however, as a Clinical Lipidologist, I have had the opportunity on a few occasions to evaluate a child or young adolescent with markedly elevated LDL cholesterol referred by pediatric and family medicine colleagues.
Article By:
Director, Lipid Clinic
Meriter Medical Group
Madison, WI
Diplomate, American Board of Clinical Lipidology
According to the 2011 National Diabetes fact sheet, 25.8 million adults and children in the United States (8.3%) have diabetes and 79 million have pre-diabetes. In 2010 alone, 1.9 million new cases of diabetes were diagnosed. In 2007, the total cost of diagnosed diabetes was $174 billion and contributed to more than 231,000 deaths in the U.S.1
Diabetes Means Cardiovascular Disease and More
Article By:
Hennepin County Medical Center
Minneapolis, MN
Diplomate, American Board of Clinical Lipidology
With the end of the Thanksgiving weekend, I must reflect on recent events in New York City, and the impact they had on our medical infrastructure. I was finally filling my car up with gasoline and in front of me was a large pickup truck filling up a huge tank of gas. I asked what it was for and was told "fuel" for hospital generators in Staten Island, New York, that are still without electricity. It reminded me that while much in New York City has returned to normal, much has not.
Article By:
President-elect, Northeast Lipid Association
Preventive CV Medicine, Lipidology and Hypertension
Clinical Assistant Professor of Medicine
NYU Medical School and Center for CV Prevention
New York, NY
Diplomate, American Board of Clinical Lipidology
I am very grateful for the opportunity to be President of the Midwest Chapter of the National Lipid Association. During this year, the Midwest Chapter made a commitment to support the activities of both the NLA and the Foundation of the NLA. Because of that commitment, we have chosen topics for the Lipid Spin that align with the great work of the Foundation and address the timely topic of familial hypercholesterolemia.
Article By:
President, Midwest Lipid Association
Director, Midwest Heart Disease Prevention Center
Assistant Professor, Loyola Stritch School of Medicine
Naperville, IL
Diplomate, American Board of Clinical Lipidology
Over the past several months, the NLA has made significant progress on a number of initiatives that reflect our commitment to advancing the science and practice of Clinical Lipidology. These initiatives also reflect the NLA's ambitions to see advances in our field manifest in new and innovative ways.
Article By:
President, National Lipid Association
Director of Preventative Cardiology
CGH Medical Center, Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois School of Medicine, Peoria, IL
Diplomate, American Board of Clinical Lipidology
The 1985 Nobel Prize in Physiology for Medicine was awarded to two physicians from Southwestern Medical Center in Dallas, Texas. Michael Brown, MD, and Joseph Goldstein, MD, received this honor "for their discoveries concerning the regulation of cholesterol metabolism."1
Article By:
Medical Director for Chronic Disease Management
Wheaton Franciscan Healthcare All Saints Cardiovascular Institute
Racine, WI
Diplomate, American Board of Clinical Lipidology
A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.
Ideas, Inventions And Innovations Blog - October 15, 2012
Following an October 2012 recommendation by the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved lomitapide for patients with homozygous FH. Lomitapide, known by the brand name Juxtapid, is produced by Aegerion Pharmaceuticals.
On Dec. 13, the European Medicines Agency announced that it failed to grant marketing approval for Kynamro (mipomersen sodium) due to concerns about its side effects. Kynamro has been in the Sanofi/Isis Pharmaceuticals pipeline as a therapy intended to treat homozygous FH. The drug is under development by Genzyme, which is owned by Sanofi. In October, the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 in favor of the treatment. The U.S. FDA is expected make a decision on Kynamro by the end of January 2013.
Join NLA faculty as they present “Myopathy and More: Getting Statins to Work in the Real World” at the AHA Scientific Sessions in Los Angeles on Monday, November 5 from 7:30 to 8:45 a.m. Part of the session will focus on results from the USAGE survey, the largest known consumer survey on statin adherence, which was conducted by the NLA in partnership with Kowa Pharmaceuticals and Eli Lilly & Co. NLA faculty for this AHA session include Jerome Cohen, MD; Matthew Ito, PharmD; and Paul Thompson, MD.